Lennox-Gastaut syndrome
Neurology · 2020–2025
5decisions
1medicine
3carried consumer input
9individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| cannabidiol Treatment of seizures associated with Lennox-Gastaut syndrome (LGS). | Jul 2025 | Recommended with restriction | input received |
| cannabidiol Adjunctive treatment of seizures in patients with Lennox-Gastaut syndrome aged 2 years and older who have not achieved adequate seizure control with at least… | Jul 2022 | Not recommended | none received |
| cannabidiol Adjunctive treatment of seizures in patients with Lennox-Gastaut syndrome aged 2 years and older who have not achieved adequate seizure control with at least… | Jul 2022 | Recommended with restriction | none received |
| cannabidiol Seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older as adjunctive therapy to standard care. | Mar 2022 | Not recommended | 9 individuals Epilepsy Society · Epilepsy Nurse Specialist Interest Group |
| cannabidiol Adjunctive therapy to treat seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS), also known as severe myoclonic epilepsy in infancy… | Jul 2020 | Recommended with restriction | input received Epilepsy Society · Epilepsy Foundation |
Who spoke
Epilepsy Society · Epilepsy Foundation · Epilepsy Nurse Specialist Interest Group
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 5 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.